U.S. Markets closed

Viking Therapeutics, Inc. (VKTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.92+0.01 (+0.17%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.91
Open6.12
Bid5.94 x 2900
Ask5.96 x 2200
Day's Range5.92 - 6.12
52 Week Range4.55 - 10.09
Volume752,052
Avg. Volume1,458,586
Market Cap438.868M
Beta (5Y Monthly)1.87
PE Ratio (TTM)N/A
EPS (TTM)-0.54
Earnings DateFeb 17, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.71
  • Bumbershoot Holdings: “Viking Therapeutics (VKTX) Struggled Right Off the Bat”
    Insider Monkey

    Bumbershoot Holdings: “Viking Therapeutics (VKTX) Struggled Right Off the Bat”

    Bumbershoot Holdings LP, an investment management firm, published its fourth quarter 2020 investor letter – a copy of which can be downloaded here. Bumbershoot Holdings L.P. generated a negative gross return of -6.61% for the full-year 2020, while its S&P 500 benchmark delivered a 16.26% return in the same period. You can view the fund’s […]

  • Viking Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference
    PR Newswire

    Viking Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference

    Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the 20th Annual Needham Virtual Healthcare Conference. The conference, which will take place April 12-15, 2021, is being conducted with a virtual format.

  • Viking Therapeutics to Participate at Upcoming Investor Conferences
    PR Newswire

    Viking Therapeutics to Participate at Upcoming Investor Conferences

    Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in three upcoming investor conferences.